Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.50
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 19.00
Low: 17.85
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing, supply & profit sharing agreement

1 Nov 2017 07:00

RNS Number : 1441V
OptiBiotix Health PLC
01 November 2017
 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Manufacturing, supply and profit sharing agreement with Knighton Foods

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a manufacturing and supply agreement with Knighton Foods, ("Knighton"). The agreement grants Knighton an exclusive licence to manufacture and supply OptiBiotix's SlimBiome® weight management technology in the United Kingdom, in return for 50% of the profit, with an agreed cost of manufacture and minimum sales price per kilogramme.

 

Knighton, a wholly owned subsidiary of Premier Foods plc, is a leading producer of a wide range of high quality, value adding, functional powdered foods, specialist ingredients and finished products, to some of the countries major supermarkets, high street coffee houses, and best-known household brands. Knighton's advanced powder technology was key to developing an improved version of SlimBiome®, providing enhanced solubility and better product presentation, greatly improving flavour and mouthfeel.

 

SlimBiome®, a patented combination of natural ingredients developed by experts to provide hunger free weight loss, will be supplied by Knighton as a specialised functional ingredient, into a wide range of finished products for use in the retail, vending, and ingredients sectors. Knighton will use their best endeavours to promote and expand the supply of SlimBiome®, bringing it to the attention of product innovation teams across their wide range of customers.

 

This agreement, with one of the UK's leading specialist ingredients suppliers, is an important step in optimising the supply chain by leveraging Knighton's purchasing power, manufacturing efficiencies and partner network to scale up the manufacture and supply of SlimBiome®.  This is an important step to meet the needs of major UK retailers and exports of SlimBiome®, and SlimBiome® containing products to Tata, and potential new partners, in the Iarge consumer markets of India and the USA.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply and profit sharing agreement with Knighton Foods. We chose Knighton due to their world leading expertise in adding value and differentiation to speciality powdered ingredients like SlimBiome®. Their development work greatly improved SlimBiome's solubility, taste and mouthfeel whilst reducing the overall cost of manufacture. We believe working with Knighton, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and the growing interest we are seeing in SlimBiome® from partners worldwide."

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0883

Liam Murray

 

FinnCap (Broker)

 

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

About Knighton Foods www.knightonfoods.com

 

Knighton Foods, based in the U.K are a leading producer of high quality specialist powdered products. Their suite of processes includes, processing, blending and packaging capabilities ranging from portion controlled sachets to 1 ton bulk containers. 

Knighton's technical and R&D capabilities have been developed over 100+ years' and deliver value and functionality to ingredients and finished products, for use in the Retail, Out of Home, and Ingredients sectors. Examples of which can be found on the shelves of the UK's leading supermarkets in some of the most recognised consumer brands, and leading chains of fast food restaurants and coffee shops.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREFLFXDBFBFBX
Date   Source Headline
30th Aug 20177:00 amRNSHalf-year Report
24th Aug 20177:00 amRNSUS product launch of LPLDL® at trade show
22nd Aug 20177:00 amRNSGlobal manufacturing & supply agreement with Sacco
31st Jul 20174:27 pmRNSTotal Voting Rights
26th Jul 20177:00 amRNSMarket launch for LPLDL® capsules in Germany
17th Jul 20177:00 amRNSSupply agreement with Pharmabiota Ltd
11th Jul 20177:00 amRNSSweetBiotix® development: Results of taste study
6th Jul 20177:00 amRNSGrant of Options
15th Jun 201712:30 pmRNSResult of AGM
15th Jun 20177:00 amRNSSupply agreement with HLH Biopharma GmbH
31st May 20177:00 amRNSHolding(s) in Company
16th May 20177:00 amRNSSuccessful launch of LPLDL and SlimBiome products
9th May 20177:00 amRNSLPLDL® Non-Exclusive European License Agreement
3rd May 20177:00 amRNSPresentation of abstract at conference
25th Apr 20178:50 amRNSFirst German sales
25th Apr 20177:00 amRNSFinal Results
4th Apr 20177:00 amRNSNotice of Results
29th Mar 201710:47 amRNSUK Investor Show attendance
24th Mar 20175:35 pmRNSHolding(s) in Company
21st Mar 201712:00 pmRNSIntention to float SkinBiotherapeutics
15th Mar 20177:00 amRNSConfirmation of Director appointments to the Board
8th Mar 20177:00 amRNSEuropean agreement with Sacco Srl
1st Mar 20177:00 amRNSLaunch of products at Vitafoods 2017
8th Feb 20179:30 amRNSExercise of Warrants and Issue of Equity
26th Jan 20172:06 pmRNSResult of General Meeting
24th Jan 20177:00 amRNSPresentation of research data
18th Jan 20177:00 amRNSAppointment of Sales and Marketing Director
17th Jan 20174:50 pmRNSHolding(s) in Company
13th Jan 20173:44 pmRNSExercise of Option and Issue of Equity
12th Jan 20177:00 amRNSPresentation of research data at ProBiota 2017
11th Jan 201710:04 amRNSExercise of Warrants and Issue of Equity
5th Jan 20177:00 amRNSAppointment of Commercial Director
3rd Jan 20177:00 amRNSIncreased investment in THWLC
23rd Dec 20167:00 amRNSNotice of General Meeting of Warrant Holders
13th Dec 20167:00 amRNSJoint Product Agreement with multinational
1st Dec 20167:00 amRNSExercise of Warrants and Issue of Equity
29th Nov 20167:00 amRNSScientific and Commercial Update
3rd Nov 20167:00 amRNSPresentation of data at European Microbiome Summit
26th Oct 20167:00 amRNSScientific and commerical update
20th Oct 20167:00 amRNSIncreased investment in SkinBiotix Ltd
5th Oct 20167:00 amRNSAppointment of a Chairman for SkinBiotix
28th Sep 20167:00 amRNSChange of Adviser
23rd Sep 20168:29 amRNSExercise of Warrants and Issue of Equity
14th Sep 20164:38 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSConsumer survey results of GoFigure products
25th Aug 20167:00 amRNSHalf-year Report
12th Aug 20163:11 pmRNSExercise of Warrants and Issue of Equity
9th Aug 20167:00 amRNSFirst products in Whole Foods Market Inc
3rd Aug 20167:00 amRNSNotice of Results
2nd Aug 20167:00 amRNSAppointment of Director of Business Development

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.